<?xml version="1.0" encoding="utf-8"?>
<doi_batch xmlns="http://www.crossref.org/schema/4.3.6" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" xmlns:ai="http://www.crossref.org/AccessIndicators.xsd" version="4.3.6" xsi:schemaLocation="http://www.crossref.org/schema/4.3.6 https://www.crossref.org/schemas/crossref4.3.6.xsd">
  <head>
    <doi_batch_id>_1568956112</doi_batch_id>
    <timestamp>1568956112</timestamp>
    <depositor>
      <depositor_name>Editor</depositor_name>
      <email_address>editor.jddt@gmail.com</email_address>
    </depositor>
    <registrant>UJPR</registrant>
  </head>
  <body>
    <journal>
      <journal_metadata>
        <full_title>Universal Journal of Pharmaceutical Research</full_title>
        <abbrev_title>Univ J Pharm Res</abbrev_title>
        <issn media_type="electronic">2456-8058</issn>
      </journal_metadata>
      <journal_issue>
        <publication_date media_type="online">
          <month>04</month>
          <day>11</day>
          <year>2018</year>
        </publication_date>
      </journal_issue>
      <journal_article xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" publication_type="full_text" metadata_distribution_opts="any">
        <titles>
          <title>FABRICATION AND CHARACTERIZATION OF EZETIMIBE SOLID DISPERSION FOR SOLUBILITY ENHANCEMENT</title>
        </titles>
        <contributors>
          <person_name contributor_role="author" sequence="first">
            <given_name>Usman Mohammed</given_name>
            <surname>Jajere</surname>
          </person_name>
          <person_name contributor_role="author" sequence="first">
            <given_name>Achadu A</given_name>
            <surname>E</surname>
          </person_name>
        </contributors>
        <jats:abstract xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1">
          <jats:p>The objective of the present study was to formulate solid dispersions (SD) of Ezetimibe to improve the solubility and dissolution rate to facilitate faster onset of action. Ezetimibe is a poorly water soluble BCS class II drug and used as a hypolipidemic agent. It has poor bioavailability (35-65%) due to its low dissolution profile in gastro intestinal tract. In the present study, eight solid dispersion formulations of Ezetimibe with polymers PEG-4000 and PEG-6000 were prepared by solvent evaporation and fusion methods.  Solid dispersion formulations were characterized by content uniformity, flow properties and in vitro dissolution studies. Present study concluded that the Ezetimibe solid dispersion formulations are a suitable approach to improve the solubility and dissolution rate of ezetimibe than pure form of drug.&#13;
Google Scholar</jats:p>
        </jats:abstract>
        <publication_date media_type="online">
          <month>01</month>
          <day>01</day>
          <year>2017</year>
        </publication_date>
        <doi_data>
          <doi>10.22270/ujpr.v2i1.R3</doi>
          <resource>http://ujpr.org/index.php/journal/article/view/33</resource>
          <collection property="crawler-based">
            <item crawler="iParadigms">
              <resource>http://ujpr.org/index.php/journal/article/download/33/24</resource>
            </item>
          </collection>
          <collection property="crawler-based">
            <item crawler="iParadigms">
              <resource>http://ujpr.org/index.php/journal/article/download/33/211</resource>
            </item>
          </collection>
          <collection property="text-mining">
            <item>
              <resource mime_type="application/pdf">http://ujpr.org/index.php/journal/article/download/33/24</resource>
            </item>
            <item>
              <resource mime_type="text/html">http://ujpr.org/index.php/journal/article/download/33/211</resource>
            </item>
          </collection>
        </doi_data>
      </journal_article>
    </journal>
  </body>
</doi_batch>
